Tag: XALL

BSGM Update & More

BioSig Technologies, Inc. BSGM

We are still tracking BSGM as we open up another trading week. If you recall one of our recent reports where we mentioned having talked about this stock on multiple occasions (April 7th, April 22nd) you can see that we’ve preen pretty hot on its trail through its whole recent run.

Our observed low on BSM came in at 3.45 shortly following our initial alert on it, and as of today in the premarket, we’re seeing high marks of as much as 9.25. That works out to an overall increase of in a matter of roughly three weeks.

The company has also just submitted an investigational new drug application with the FDA for its orally administered coronavirus treatment. We’re going to be very interested to continue keeping an eye on the activity in BSGM which has now been running hard for a full seven sessions.

Options Ideas 

Facebook’s announcement that it would be entering the multi-user conferencing arena, has us temporarily bullish on FB and bearish on ZM. We will formulate some quick-strike options ideas accordingly;

FB Weekly $192.50-197.50 Calls
ZM Weekly $160-155 Puts

Extended Watchlist:
AABB, FCEL, TPTW, UVFT, VODG, VXRT, XALL

Blue Horseshoe Stocks: PIRS Review & More

Pieris Pharmaceuticals Inc. PIRS – Review

Of all the types of plays we search for, bottom watch plays can require the most amount of patience as compared to other quick-strike ideas that we formulate. We highlighted PIRS as such back in mid-February, and over the past quarter, the stock has produced some very favorable results in two distinct runs.

When we initially signaled our interest in this stock, or shortly thereafter, it was trading for as little as 2.83 and over the course of the next two months, it gradually made its way to 4.00 (+41%). After a pullback down near its original level at 2.81 halfway through last month, the stock has begun to run once again. This time it has reached all new highs, with the stock changing hands for as much as 4.68/share on Friday. That second push allowed us to see an overall increase of 67%

We wouldn’t be at all surprised to have to come back to PIRS once again in the near future. In addition to the company’s joint clinical venture with pharma super giant AstraZeneca, the stock itself has recently received analyst upgrades that could just be the beginning of PIRS’s next leg-up.

Xalles Holdings, Inc. XALL

We are also looking at the incredible momentum recently built up by XALL, which has been assisted by the resurgence of Bitcoin here in 2019, which began in January in the mid-$3000 range, and has persisted to the present time to the current highs near $8700.

The company also recently decreased its public float by around 50%, making it that much easier for the stock to move. We’ll be interested to continue to monitor its progress, especially if the latest Bitcoin boom continues to persist as it has in recent months.

Extended Watchlist:
DRRX, CBLK, BLNK, CTRV, MOSY, SNSS, NVCN, ATVI, LAHO(>>News Alert)